IP Library › Patent Application 12238403
Patent Application
App. No. 12/238,403

DEHYDROEPIANDROSTERONE SULFATE DIHYDRATE INHALATION COMPOSITIONS AND METHODS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/238,403
Abstract

The invention relates to inhalation compositions derived from dehydroepiandrosterone sulfate. The compositions of the invention involve liquid nebulizer formulations prepared from dehydroepiandrosterone sulfate dihydrate. The compositions of the invention comprise water and chloride ion. The liquid nebulizer formulations can be used to treat patients suffering from asthma or COPD.

Claims (13)

1 . A liquid nebulizer formulation prepared by mixing dehydroepiandrosterone sulfate dihydrate (DHEA-S), water, and halide ions.

2 . The liquid nebulizer formulation of claim 1 wherein the halide ions comprise chloride ions.

3 . The liquid nebulizer formulation of claims 1 wherein the halide concentration in the formulation is 20 mM or lower.

4 . The liquid nebulizer formulation of claims 2 wherein the chloride concentration in the formulation is 20 mM or lower.

5 . The liquid nebulizer formulation of claim 1 wherein the formulation also comprises sodium.

6 . The liquid nebulizer formulation of claim 2 wherein at least some of the chloride in the formulation is added in the form of a salt.

7 . The liquid nebulizer formulation of claim 6 wherein at least some of the chloride in the formulation is provided by the addition of sodium chloride.

8 . The liquid nebulizer formulation of claim 7 wherein the sodium chloride is present in the formulation at 0.12% or less.

9 . The liquid nebulizer formulation of claim 1 wherein the dehydroepiandrosterone sulfate dihydrate used to prepare the formulation is crystalline dehydroepiandrosterone sulfate dihydrate.

10 . The liquid nebulizer formulation of claim 1 wherein the level of dehydroepiandrosterone sulfate in the formulation is between about 5 mg/mL and about 10 mg/mL.

11 . A kit comprising a container comprising the liquid nebulizer formulation of claim 1 .

12 . A method for treatment of asthma, comprising administering to a subject in need of such treatment by inhalation a therapeutically effective amount of the dehydroepiandrosterone sulfate in a liquid nebulizer formulation of claim 1 .

13 . A method for treatment of chronic obstructive pulmonary disease, comprising administering to a subject in need of such treatment by inhalation a therapeutically effective amount of the dehydroepiandrosterone sulfate in a liquid nebulizer formulation of claim 1 .